ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Review uri icon


MeSH Major

  • Anti-Inflammatory Agents, Non-Steroidal
  • Gastrointestinal Hemorrhage
  • Helicobacter Infections
  • Helicobacter pylori
  • Platelet Aggregation Inhibitors


  • In appropriate patients oral antiplatelet therapy decreases ischemic risks, but this therapy may increase bleeding complications. Of the major bleeding that occurs, the largest proportion is due to GI hemorrhage. Concomitant use of NSAIDs further raises the risk of GI bleeding. Gastroprotection strategies consist of use of PPIs in patients at high risk of GI bleeding and eradication of H. pylori in patients with a history of ulcers. Communication between cardiologists, gastroenterologists, and primary care physicians is critical to weigh the ischemic and bleeding risks in an individual patient who needs antiplatelet therapy but who is at risk for or develops significant GI bleeding. © 2008 American College of Cardiology Foundation, American College of Gastroenterology, and the American Heart Association, Inc.

publication date

  • October 28, 2008



  • Review



  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.jacc.2008.08.002

PubMed ID

  • 19017521

Additional Document Info

start page

  • 1502

end page

  • 17


  • 52


  • 18